Figma Shares Indicated To Open $105/$110
CHARLOTTE, N.C. - Dentsply Sirona (NASDAQ:XRAY) reported fourth-quarter results that missed revenue expectations and provided weaker-than-expected guidance for 2025 on Thursday.,
The company’s shares were down -2.13% in after-hours trading.
The dental equipment maker posted adjusted earnings per share of $0.26 for Q4, beating analyst estimates of $0.43. However, revenue fell 10.6% YoY to $905 million, below the consensus forecast of $922.82 million.
For the full year 2024, Dentsply Sirona reported net sales of $3.79 billion, down 4.3% compared to 2023. Organic sales decreased 3.5%, including a 1.2% negative impact from its Byte clear aligner business.
"While we were pleased to see improvement in several areas of the business, Byte, persistent macro pressures and competitive dynamics negatively impacted Q4 and 2024 full year results," said CEO Simon Campion.
Looking ahead, the company expects 2025 revenue between $3.5 billion and $3.6 billion, below analyst projections of $3.74 billion. Adjusted EPS guidance of $1.80 to $2.00 also fell short of the $1.91 consensus estimate.
Dentsply Sirona anticipates organic sales to decline 2% to 4% in 2025, including an expected 2% headwind from Byte.
The company’s Q4 results and cautious outlook highlight ongoing challenges in the dental market, though management expressed confidence that transformation initiatives will drive margin expansion and earnings growth in 2025 despite the difficult external environment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.